Current Phase II investigational therapies for insomnia

被引：31
作者：
Zisapel, Nava [1 ,2 ]
机构：
[1] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiol, IL-69978 Tel Aviv, Israel
[2] Neurim Pharmaceut, Tel Aviv, Israel
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2015年 / 24卷 / 03期
关键词：
drugs; GABA; histamine; insomnia; melatonin; orexin; receptors; serotonin; PROLONGED-RELEASE MELATONIN; DOXEPIN; MG; AUTISM SPECTRUM DISORDERS; PLACEBO-CONTROLLED TRIAL; SMITH-MAGENIS-SYNDROME; SLEEP DISORDERS; DOUBLE-BLIND; CONSENSUS STATEMENT; ALZHEIMERS-DISEASE; OUTPATIENT TRIAL;
D O I：
10.1517/13543784.2015.987340
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Introduction: Insomnia is typified by a difficulty in sleep initiation, maintenance and/or quality (non-restorative sleep) resulting in significant daytime distress. Areas covered: This review summarizes the available efficacy and safety data for drugs currently in the pipeline for treating insomnia. Specifically, the authors performed MEDLINE and internet searches using the keywords 'Phase II' and 'insomnia'. The drugs covered target GABAA (zaleplon-CR, lorediplon, EVT-201), orexin (filorexant, MIN-202), histamine-H1 (LY2624803), serotonin 5-HT2A (ITI-007), melatonin/serotonin5-HT1A (piromelatine) and melatonin (indication expansions of prolonged-release melatonin and tasimelteon for pediatric sleep and circadian rhythm disorders) receptors. Expert opinion: Low-priced generic environments and high development costs limit the further development of drugs that treat insomnia. However, the bidirectional link between sleep and certain comorbidities may encourage development of specific drugs for comorbid insomnia. New insomnia therapies will most likely move away from GABAAR receptors' modulation to more subtle neurological pathways that regulate the sleep-wake cycle.
引用
收藏
页码：401 / 411
页数：11
相关论文
共 98 条
[31]   Sleep disturbance is associated with cardiovascular and metabolic disorders [J].
Grandner, Michael A. ;
Jackson, Nicholas J. ;
Pak, Victoria M. ;
Gehrman, Philip R. .
JOURNAL OF SLEEP RESEARCH, 2012, 21 (04) :427-433
[32]   Melatonin reduces night blood pressure in patients with nocturnal hypertension [J].
Grossman, Ehud ;
Laudon, Moshe ;
Yalcin, Ridvan ;
Zengil, Hakan ;
Peleg, Edna ;
Sharabi, Yehonatan ;
Kamari, Yehuda ;
Shen-Orr, Zila ;
Zisapel, Nava .
AMERICAN JOURNAL OF MEDICINE, 2006, 119 (10) :898-902
[33]   SLEEP DISORDERS AND MELATONIN RHYTHMS IN ELDERLY PEOPLE [J].
HAIMOV, I ;
LAUDON, M ;
ZISAPEL, N ;
SOUROUJON, M ;
NOF, D ;
SHLITNER, A ;
HERER, P ;
TZISCHINSKY, O ;
LAVIE, P .
BRITISH MEDICAL JOURNAL, 1994, 309 (6948) :167-167
[34]  
Hauri PJ, 1997, ACTA NEUROL BELG, V97, P113
[35]  
Hiromasa Shuichi, 2013, Nihon Rinsho, V71, P181
[36]   Sleep Duration and Sleep Quality in Relation to 12-Year Cardiovascular Disease Incidence: The MORGEN Study [J].
Hoevenaar-Blom, Marieke P. ;
Spijkerman, Annemieke M. W. ;
Kromhout, Daan ;
van den Berg, Julia F. ;
Verschuren, W. M. Monique .
SLEEP, 2011, 34 (11) :1487-1492
[37]   Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant [J].
Hoever, P. ;
de Haas, S. ;
Winkler, J. ;
Schoemaker, R. C. ;
Chiossi, E. ;
van Gerven, J. ;
Dingemanse, J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) :593-600
[38]   PREVALENCE AND TREATMENT OF INSOMNIA IN GENERAL-PRACTICE - A LONGITUDINAL-STUDY [J].
HOHAGEN, F ;
RINK, K ;
KAPPLER, C ;
SCHRAMM, E ;
RIEMANN, D ;
WEYERER, S ;
BERGER, M .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1993, 242 (06) :329-336
[39]   Pharmacological treatment of sleep disturbance in developmental disabilities: A review of the literature [J].
Hollway, Jill A. ;
Aman, Michael G. .
RESEARCH IN DEVELOPMENTAL DISABILITIES, 2011, 32 (03) :939-962
[40]   A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression [J].
Howland, Robert H. .
DRUG SAFETY, 2011, 34 (09) :709-731
12345678910